46 companies each receive up to £1 million funding in latest rounds of SBRI Healthcare programme.
SBRI Healthcare, an NHS England funded initiative to develop innovative products that address unmet health needs, today announced a further 46 small companies will share over £20 million development funding in the latest rounds of the programme. The award is across two competitions each of which represents a distinct product development phase with successful projects selected on their potential value to the health service, patient benefit and the opportunity to back thriving businesses.
The awards go to companies working in the priority healthcare areas of:
Phase 1: Product feasibility (£2.5 million, 26 companies) – Child & Maternal Health, Integrated Care, Learning Disabilities, Medicines Adherence and Musculoskeletal.
Phase 2: Prototype development (£18.5 million, 20 companies) – Cancer, Cardiovascular, COPD, Diabetes, Mental Health, Patient Safety and Research Tools.
Karen Livingstone, National Director, SBRI Healthcare, commented: “SBRI Healthcare is powering innovative small companies to develop new solutions for challenges the NHS has struggled with for many years. The SBRI Healthcare programme is led by the Academic Health Science Networks who ensure that projects answer a real and compelling need in patient care. We are delighted with the success of the programme to date and that it continues to go from strength to strength. There are now more than 100 companies in the SBRI Healthcare portfolio, a pipeline of products evaluated at over £1bn and over 20m patients due to beneﬁt – this is really great news for healthcare and economic growth.
Winners are being announced to coincide with SPARK 2014, SBRI Healthcare’s inaugural conference and exhibition on 10th December, QEII Conference Centre, Westminster, London.
SBRI 7 Phase 1: Advanced Digital Innovations (UK) Ltd, Armourgel Ltd, azureindigo, Bering Ltd, BioSensors Ltd, Biovici Ltd, Blue Maestro Ltd,Cambridge Respiratory Innovations Ltd, Cupris Ltd, Digital Creativity in Disability Ltd, Disabled Living Foundation, Docobo Ltd, Folium Optics Ltd, Know Your Own Health Ltd, Maldaba Ltd, Melton Health Care Technologies Ltd, MIRA Rehab, Peacocks Medical Group Ltd, Red Embedded Systems Ltd, Selective Antibodies Ltd, Sensixa Ltd, Taragenyx, Therakind Ltd, University of Central Lancashire, We Predict Ltd
SBRI 5 Phase 2: Aseptika Ltd, Astrimmune Ltd, Cambridge Respiratory Innovations Ltd, Capillary Film Technology Ltd, Cardiocity Ltd, Doctor Communication Solutions Ltd, HealthQuest Solutions Ltd, i2r Medical Ltd, Inotec AMD Ltd, Isansys Lifecare Ltd, Lightpoint Medical Ltd, Mayden House Ltd, Oncascan Ltd, Owlstone Ltd, Oxford Medical Diagnostics Ltd, Plessey Group Holdings Ltd, ProReal Ltd, TiKa Diagnostics Ltd, UCL Partners Ltd, ViVO Smart Medical Devices Ltd.
*Subject to due diligence and agreeing contracts.